Drug updated on 4/18/2024
| Dosage Form | Tablet (oral; 200 mg) |
| Drug Class | RAS GTPase family inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.
Summary
- Adagrasib (Krazati) is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy.
- Two studies were reviewed, focusing on the efficacy and safety of adagrasib in treating KRAS^G12C-mutated solid tumors, including non-small cell lung cancer.
- The objective response rate (ORR) was reported as 31% in a study that included 18 studies with 1224 patients. However, another study focused specifically on NSCLC showed an ORR of 37%, suggesting potential heightened efficacy within lung cancer populations.
- There is a notable difference in the incidence of grade ≥3 adverse events between different types of solid tumors being treated; it's lower for broader analysis (29%) compared to an NSCLC-specific study (44%), indicating that the safety profile might vary significantly depending upon the patient population and type of tumor.
- Patients with KEAP1 co-mutation may not benefit as significantly from these treatments due to inferior response rates. This underscores the significance of personalized treatment approaches within this domain.
- Compared to other KRAS^G12C inhibitors, adagrasib demonstrates considerable efficacy and manageable safety profile consistent with collective data presented for this class but direct comparisons are limited by available data.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Krazati (adagrasib) Prescribing Information. | 2022 | Mirati Therapeutics, Inc. 3545 Cray Court San Diego, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis. | 2024 | Pharmacological Research |
| Efficacy and toxicity of drugs targeting KRASG12C mutation in non-small cell lung cancer: a meta-analysis | 2023 | Expert review of anticancer therapy |